We are live on ! Find out more
KTTA icon

Pasithea Therapeutics
KTTA

9 hedge funds and large institutions have $1.03M invested in Pasithea Therapeutics in 2022 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

547% more capital inflows, than outflows

Capital inflows: $231K | Capital outflows: $35.7K

300% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 1

0.25% more ownership

Funds ownership: 2.82% → 3.07% (+0.25%)

10% less funds holding

Funds holding: 10 → 9 (-1)

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

Holders
9
Holders Change
-1
Holders Change %
-10%
% of All Funds
0.15%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
4
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$95.9K
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$92.6K
3
Old Well Partners
Old Well Partners
North Carolina
+$38.7K
4
Tower Research Capital (TRC)
Tower Research Capital (TRC)
New York
+$3.99K
5
Wells Fargo
Wells Fargo
California
+$23

Top Sellers

Rank Fund Capital Flow
1
Virtu Financial
Virtu Financial
New York
-$15K
2
StoneX Group
StoneX Group
New York
-$12.1K
3
UBS Group
UBS Group
Switzerland
-$8.62K

KTTA Hedge Fund Activity: Q3 2022 in Review

9 of the 5,833 institutional investors tracked by Wall St. Rank reported a position in Pasithea Therapeutics (KTTA) for Q3 2022, worth a combined $1.03M — up 56% from $662K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of KTTA and 1 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 4 added.

The largest buyer was Vanguard Group, adding an estimated $95.9K. The largest seller was Virtu Financial, exiting entirely with an estimated $15K sold.

  • 9 institutional investors held Pasithea Therapeutics (KTTA) as of Q3 2022, down from 10 in Q2 2022.
  • Funds reported $1.03M of Pasithea Therapeutics stock for Q3 2022, up 56% quarter-over-quarter.
  • 1 fund opened new Pasithea Therapeutics positions in Q3 2022 and 2 closed out, a net change of -1 holder.
  • The largest Pasithea Therapeutics buyer in Q3 2022 was Vanguard Group, an estimated $95.9K added.
  • The largest Pasithea Therapeutics seller in Q3 2022 was Virtu Financial, an estimated $15K sold.

Based on aggregated 13F filings for Q3 2022.